Skip to contentR
Revolution Medicines, Inc.
R
RVMDWRevolution Medicines, Inc. Q1 2025 · 10-Q
Revenue—
Net Income-$213.42M-$213.42MN/M vs Q1 2024 EPS Diluted-$1.13-$1.13N/M vs Q1 2024 Operating Income-$240,760,000N/M Operating Cash Flow-$194,435,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revolution Medicines, Inc. · CIK 1628171 · Engraved from SEC EDGAR
Free Cash Flowderived-$197,701,000N/M ended Mar 31, 2025 · filed May 7, 2025 · 37 d after period end